{"id":37218,"date":"2024-03-20T12:00:00","date_gmt":"2024-03-20T12:00:00","guid":{"rendered":"https:\/\/skan.com\/?page_id=37218"},"modified":"2024-03-20T12:44:18","modified_gmt":"2024-03-20T12:44:18","slug":"civica-skan-groninger-cooperation","status":"publish","type":"page","link":"https:\/\/skan.com\/en\/civica-skan-and-groningers-cooperation-story\/","title":{"rendered":"Civica, SKAN and groninger’s cooperation story"},"content":{"rendered":"\t\r\n\t
\r\n\t\t\t\t
\r\n\t\t\t
\r\n\t\t\t\t\t\t\t\t\t
\r\n\t\t\t\t\t\t
\r\n\t\t\t\t\t\t\t

Cooperation between Civica, SKAN and groninger<\/h1>\n

The journey to end drug shortages and make medications affordable in the United States<\/h2>\n

 <\/p>\n

In this narrative, we delve into a unique collaboration that has significantly impacted the pharmaceutical landscape in the United States. This story revolves around Civica, a non-profit generic drug company, and its mission to ensure accessibility and affordability of essential medications for all patients in the US. To reach this ambitious goal, Civica chose the experienced market leaders groninger + SKAN to technologically equip their new Virginia facility.<\/p>\n

Learn more about this inspiring collaboration in the video!<\/p>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t

\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t\tScroll down\t\t\t\t\t\t\t\t<\/a>\r\n\t\t\t\t\t\t\t<\/div>\r\n\t\t\t\t\t\t<\/div>\r\n\t\t\t\t\t<\/div>\r\n\t\t\t\t\t \t\t\t\t\t
\r\n\t\t\t\t\t\t
\r\n \r\n \r\n \r\n \"Ned <\/picture>\r\n \r\n \r\n <\/circle>\r\n <\/path>\r\n <\/svg>\r\n <\/a>\r\n <\/div>\r\n \t\t\t\t\t<\/div>\r\n\t \t\t\t<\/div>\r\n\t\t<\/div>\r\n\t<\/section>\r\n\t
<\/div>\r\n\n\n\t\r\n\t
\r\n\t\t
\r\n\t\t\t
\r\n\t\t\t\t\t\t\t\t\t
\r\n\t\t\t\t\t\t
\r\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t
\r\n\t\t

Addressing healthcare challenges in the US<\/h2>\n

Access to essential medications, particularly life-saving drugs like insulin, remains a significant challenge in the American healthcare landscape. Vital medications often hover beyond reach due to exorbitant prices and persistent scarcities. Civica’s \u201creason why\u201d for their foundation in 2018 is clear: to confront these challenges directly by producing generic sterile injectables that are consistently in short supply and offering others at low, sustainable prices.<\/p>\n

\n

\u201eWe don\u2019t believe people should have to choose between food, rent and their insulin.\u201c (Ned McCoy, Civica\u2019s CEO)<\/p>\n<\/blockquote>\n

Collaborating with hospitals, health systems, and philanthropies, Civica ensures reliable access to quality medications for patients across the US. From addressing shortages in hospitals to tackling the insulin crisis, Civica’s dedication to its mission is truly inspiring.<\/p>\n

As of March 2024, Civica was already able to provide 160 million doses of generic medications, enough to help treat 70 million patients. With their new, state-of-the-art Virginia facility, Civica will continue to grow exponentially the numbers of patients they help serve by providing quality, essential medicines for years to come.<\/p>\n\t<\/div>\r\n\t\t\t\t\t\t\t \t\t\t\t\t\t<\/div>\r\n\t\t\t\t\t<\/div>\r\n\t\t\t\t\t\t\t\t\t\t\t\t\t